Skip to main content

Anaphylaxis

3
Pipeline Programs
6
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Medica Corp
Medica CorpMA - Bedford
1 program
1
A: Epinephrine injectionPhase 1/21 trial
Active Trials
NCT06205134Completed12Est. Feb 2024
Bausch + Lomb
Bausch + LombNJ - Bridgewater
1 program
1
Part 1Phase 1
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
1
Part 1Phase 11 trial
Active Trials
NCT03282929Completed43Est. Oct 2018
Innovation Pharmaceuticals
1 program
Device: AnapphylaxisN/A1 trial
Active Trials
NCT02854969Completed100Est. Jul 2017
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
Intravenous heparinN/A1 trial
Active Trials
NCT00657228WithdrawnEst. Dec 2010
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
EpinephrinePHASE_21 trial
Active Trials
NCT00890162Completed16Est. May 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Allergy TherapeuticsEpinephrine
Medica CorpA: Epinephrine injection
Bausch HealthPart 1
Innovation PharmaceuticalsDevice: Anapphylaxis
City TherapeuticsIntravenous heparin

Clinical Trials (5)

Total enrollment: 171 patients across 5 trials

NCT00890162Allergy TherapeuticsEpinephrine

A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis

Start: Apr 2009Est. completion: May 201916 patients
Phase 2Completed
NCT06205134Medica CorpA: Epinephrine injection

Comparative Bioavailability of Intranasal Epinephrine

Start: Aug 2023Est. completion: Feb 202412 patients
Phase 1/2Completed
NCT03282929Bausch HealthPart 1

Study to Explore the Pharmacokinetics and Pharmacodynamics of Epinephrine in Healthy Male and Female Subjects With Different Skin to Muscle Depth (STMD)

Start: Mar 2017Est. completion: Oct 201843 patients
Phase 1Completed
NCT02854969Innovation PharmaceuticalsDevice: Anapphylaxis

Satisfaction of Patient With Anaphylaxis in the Use of a Medical Device

Start: May 2016Est. completion: Jul 2017100 patients
N/ACompleted
NCT00657228City TherapeuticsIntravenous heparin

Intravenous Heparin as an Adjunct for the Treatment of Anaphylactic Reactions in an Emergency Department

Start: Dec 2009Est. completion: Dec 2010
N/AWithdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.